1 0

Cart

Inquiry

Product Gene Keyword

Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein

Recombinant Mouse Anti-IAV HA Antibody (HC19)

CAT#: PABW-077

Recombinant Mouse Antibody (HC19) is capable of binding to IAV HA, expressed in Chinese Hamster Ovary cells (CHO).

Published Data

Figure 1 Affinities of IgG and Fab measured by using biolayer interferometry.

Figure 1 Affinities of IgG and Fab measured by using biolayer interferometry.

Binding sensorgrams show binding of BHA to immobilized HC19 IgG (blue), HC19 Fab (green), FI6v3 IgG (red), and FI6v3 Fab (orange).

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 2 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

Figure 2 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

HC19 inhibition of membrane disruption is enhanced through bivalent interactions between IgG and HA on X31 virus, even at subsaturating concentrations, where aggregation was observed by DLS. Fab binding has little impact on membrane disruption inhibition.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 3 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

Figure 3 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

Extents of inhibition of lipid mixing by IgG and Fab are similar, suggesting that bivalency may not play a large role in fusion inhibition for HC19.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 4 Neutralization assay measuring TCID50.

Neut

Figure 4 Neutralization assay measuring TCID50.

Antibody-mediated neutralization of influenza virus was evaluated by measuring the TCID50 of influenza virus. IgGs for both FI6v3 and HC19 displayed stronger neutralization than did the respective Fabs. While HC19 Fab could neutralize virus to some degree, FI6v3 Fab did not exhibit a significant ability to neutralize the virus (*, P> 0.05; **, P < 0.01).

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 5 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

Figure 5 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

As the ratio of IgG/HA increases, HC19 aggregates virus particles, with peak aggregation occurring at 2:1 ratios.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 6 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

Figure 6 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

Negative-stain micrographs further illustrate the extent of aggregation as the ratio of IgG/HA increases.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 7 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 1 Inhibition of wild-type and mutant NA activity by NC10. Figure 2 Inhibition of wild-type and mutant NA activity by NC10. Figure 3 ELISA measuring binding of mutant NAs to NC10. Figure 4 Correlation between A405 ELISA reading and amount of NA measured by enzyme activity using the fluorogenic substrate 4-methylumbelliferyl-Nacetylneuraminic acid.Figure 5 Scatchard plots of inhibition of wild-type and mutant NAs by NC10. Figure 6 Scatchard plots of the ELISA results to determine apparent Kd in the solid phase assay.Figure 1 Loss of mAb OPG2 binding following substitution of β3 Asp217 or Glu220.Figure 1 Monoclonal antibodies 1H10 and 1A5 do not bind in the presence of prebound 2A8.Figure 1 Fluorescence microscopic images of LS174T cells. The relative mean fluorescence intensity in the tumor and liver regionsRepresentative images of dissected organs of athymic nude miceRepresentative images of dissected organs of athymic nude miceTissue-to-heart ratios for (B) the mice sacrificed 2 hours after injection and (C) the mice sacrificed 18 hours after injection.Figure 1 (A) HEK/CFP-HA-DAT cells were treated with 1 μM PMA or Me2SO for 15 min,lysed, and DAT was precipitated with the HA11 antibody. Figure 2 (B) the recom-binant four-ubiquitin Lys63-linked, Lys48-linked, and linear chains wereelectrophoresed and blotted with the same antibodies that were used toprobe DAT immunoprecipitates in A.Figure 3 HEK/CFP-HA-DAT cells were treated with 1 µM PMA for 15 min, lysed and DAT was precipitated with the HA11 antibody. Figure 4 Quantification of experiments presented in Figure 3. Figure 1 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo-BSA. Figure 2 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko-BSA. Figure 3 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko(2→4)Kdo-BSA. Figure 4 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Ko-BSA. Figure 5 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Kdo-BSA. Figure 6 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 7 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 8 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 9 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 10 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 1 Effect of 17b on bNAb and non-bNAb binding to monomeric HXBc2 gp120 core by Sandwich ELISA assay. Figure 2 ELISA binding profiles of human CD4bs and non-CD4bs MAbs (left), and selected sera of Imm 3 and Imm 7 (right) from complex-GLA immunized rabbit group tested with CD4bs bNAb probes, RSC3/G367R and RSC3 Δ371I/P363N.Figure 3 The binding kinetics of CD4bs MAb b13 and representative rabbit MAbs 30-9 and 46-1 to HXBc2 core and RSC3 core. Figure 4 Surface plasmon resonance analysisFigure 1 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 1 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 1 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 2 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 3 Acidic residue D101 of AL-57 is critical for binding.

Figure 7 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 1 Inhibition of wild-type and mutant NA activity by NC10. Figure 2 Inhibition of wild-type and mutant NA activity by NC10. Figure 3 ELISA measuring binding of mutant NAs to NC10. Figure 4 Correlation between A405 ELISA reading and amount of NA measured by enzyme activity using the fluorogenic substrate 4-methylumbelliferyl-Nacetylneuraminic acid.Figure 5 Scatchard plots of inhibition of wild-type and mutant NAs by NC10. Figure 6 Scatchard plots of the ELISA results to determine apparent K_d in the solid phase assay.Figure 1 Loss of mAb OPG2 binding following substitution of β3 Asp²¹⁷ or Glu²²⁰.Figure 1 Monoclonal antibodies 1H10 and 1A5 do not bind in the presence of prebound 2A8.Figure 1 Fluorescence microscopic images of LS174T cells. The relative mean fluorescence intensity in the tumor and liver regionsRepresentative images of dissected organs of athymic nude miceRepresentative images of dissected organs of athymic nude miceTissue-to-heart ratios for (B) the mice sacrificed 2 hours after injection and (C) the mice sacrificed 18 hours after injection.Figure 1 (A) HEK/CFP-HA-DAT cells were treated with 1 μM PMA or Me₂SO for 15 min,lysed, and DAT was precipitated with the HA11 antibody. Figure 2 (B) the recom-binant four-ubiquitin Lys63-linked, Lys48-linked, and linear chains wereelectrophoresed and blotted with the same antibodies that were used toprobe DAT immunoprecipitates in A.Figure 3 HEK/CFP-HA-DAT cells were treated with 1 µM PMA for 15 min, lysed and DAT was precipitated with the HA11 antibody. Figure 4 Quantification of experiments presented in Figure 3. Figure 1 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo-BSA. Figure 2 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko-BSA. Figure 3 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko(2→4)Kdo-BSA. Figure 4 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Ko-BSA. Figure 5 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Kdo-BSA. Figure 6 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 7 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 8 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 9 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 10 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 1 Effect of 17b on bNAb and non-bNAb binding to monomeric HXBc2 gp120 core by Sandwich ELISA assay. Figure 2 ELISA binding profiles of human CD4bs and non-CD4bs MAbs (left), and selected sera of Imm 3 and Imm 7 (right) from complex-GLA immunized rabbit group tested with CD4bs bNAb probes, RSC3/G367R and RSC3 Δ371I/P363N.Figure 3 The binding kinetics of CD4bs MAb b13 and representative rabbit MAbs 30-9 and 46-1 to HXBc2 core and RSC3 core. Figure 4 Surface plasmon resonance analysisFigure 1 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 1 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 1 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 2 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 3 Acidic residue D101 of AL-57 is critical for binding.

Digestion of IgG into monovalent Fab arms fails to aggregate influenza virus X31, emphasizing the complex binding that occurs between bivalent IgG and HA
presented on the virus surface. Bar = 200 nm.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

(A and B) A 4.4-nm-thick computational slice through HC19 IgG-complexed virus at a ratio of 1:6 (IgG/HA). Black arrowheads point toward IgG-cross-linked HA trimers on the surface of individual particles, and expanded views of these interactions are shown in the insets.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

A 4.4-nm-thick computational slice through HC19 IgG-complexed virus at a ratio of 1:3 (IgG/HA). The radial density average at the interface between two virus particles was measured so that the distribution of lipid and protein components could be assigned. The blue box indicates the measured area used for the radial density plot.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

(D and E) Computational slices (8.0 nm thick) through HC19 IgG-complexed virus at a ratio of 1:2 (IgG/HA) illustrating extensive aggregation that occurs. Bar = 25 nm.

Williams, J. (2018). Mechanisms of antibody-mediated neutralization targeting viral glycoproteins (Doctoral dissertation).

❮

Figure 1 Affinities of IgG and Fab measured by using biolayer interferometry.

Figure 2 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

Figure 3 Fluorescence fusion assay monitors antibody-mediated inhibition of HA function by tracking dequenching of the fluorescent dyes SRB, indicating membrane disruption, and DiD, indicating lipid mixing.

Figure 4 Neutralization assay measuring TCID50.

Figure 5 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

Figure 6 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.

Figure 7 Dynamic light scattering monitors the time- and concentration-dependent aggregation of influenza virus X31 by HC19 IgG.Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur. Figure 1 Inhibition of wild-type and mutant NA activity by NC10. Figure 2 Inhibition of wild-type and mutant NA activity by NC10. Figure 3 ELISA measuring binding of mutant NAs to NC10. Figure 4 Correlation between A405 ELISA reading and amount of NA measured by enzyme activity using the fluorogenic substrate 4-methylumbelliferyl-Nacetylneuraminic acid.Figure 5 Scatchard plots of inhibition of wild-type and mutant NAs by NC10. Figure 6 Scatchard plots of the ELISA results to determine apparent Kd in the solid phase assay.Figure 1 Loss of mAb OPG2 binding following substitution of β3 Asp217 or Glu220.Figure 1 Monoclonal antibodies 1H10 and 1A5 do not bind in the presence of prebound 2A8.Figure 1 Fluorescence microscopic images of LS174T cells. The relative mean fluorescence intensity in the tumor and liver regionsRepresentative images of dissected organs of athymic nude miceRepresentative images of dissected organs of athymic nude miceTissue-to-heart ratios for (B) the mice sacrificed 2 hours after injection and (C) the mice sacrificed 18 hours after injection.Figure 1 (A) HEK/CFP-HA-DAT cells were treated with 1 μM PMA or Me2SO for 15 min,lysed, and DAT was precipitated with the HA11 antibody. Figure 2 (B) the recom-binant four-ubiquitin Lys63-linked, Lys48-linked, and linear chains wereelectrophoresed and blotted with the same antibodies that were used toprobe DAT immunoprecipitates in A.Figure 3 HEK/CFP-HA-DAT cells were treated with 1 µM PMA for 15 min, lysed and DAT was precipitated with the HA11 antibody. Figure 4 Quantification of experiments presented in Figure 3. Figure 1 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo-BSA. Figure 2 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko-BSA. Figure 3 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko(2→4)Kdo-BSA. Figure 4 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Ko-BSA. Figure 5 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Kdo-BSA. Figure 6 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 7 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 8 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 9 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 10 Surface plasmon resonance of S67-27 binding to Kdo analogs.Figure 1 Effect of 17b on bNAb and non-bNAb binding to monomeric HXBc2 gp120 core by Sandwich ELISA assay. Figure 2 ELISA binding profiles of human CD4bs and non-CD4bs MAbs (left), and selected sera of Imm 3 and Imm 7 (right) from complex-GLA immunized rabbit group tested with CD4bs bNAb probes, RSC3/G367R and RSC3 Δ371I/P363N.Figure 3 The binding kinetics of CD4bs MAb b13 and representative rabbit MAbs 30-9 and 46-1 to HXBc2 core and RSC3 core. Figure 4 Surface plasmon resonance analysisFigure 1 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S54-10 Fab binding to different Kdo antigensFigure 1 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 2 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 3 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 4 Surface plasmon resonance analysis of S73-2 Fab binding to different Kdo antigensFigure 1 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 2 SPR analysis of binding by the αL I domains to Abs AL-57 and MHM24. Figure 3 Acidic residue D101 of AL-57 is critical for binding.

Figure 8 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

Figure 9 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

Figure 10 HC19 IgG-mediated cross-linking of HA on the surface of intact X31 influenza occurs between adjacent antigens on single particles and between antigens on separate particles, causing aggregation to occur.

❯

Specifications

Immunogen
H3N2 IAV hemagglutinin

Host Species
Mouse

Derivation
Mouse

Type
IgG

Specificity
Tested positive against native IAV HA

Species Reactivity
H3N2 IAV

Clone
HC19

Applications
Can be useful in applications such as: Neutralization

Product Property

Purity
>95% by SDS-PAGE and HPLC analysis

Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Target

Alternative Names
HA; hemagglutinin; HA1; HA2

Gene ID
3655151

UniProt ID
Q464B9

REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS

Inquiry

Navs

Customer Review

There are currently no Customer reviews or questions for PABW-077. Click the button above to contact us or submit your feedback about this product.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

Datasheet - PABW-077.pdf

MSDS

MSDS - PABW-077.pdf

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "Clone HC19"

CAT
Product Name

See other products for "IAV HA"

Select a product category from the dropdown menu below to view related products.

CAT	Product Name	Application	Type
DrMAB-116	Recombinant Human Anti-IAV HA Antibody, clone FLD21	NTRL	IgG
PABL-587	Recombinant Human Anti-IAV HA Antibody (AVFluIgG03)	Neut	IgG
MRO-2168CQ	Recombinant Mouse Anti-IAV HA Antibody (MRO-2168CQ)	WB, IF, IP, IHC-P, IHC-Fr	Mouse antibody
MRO-2169CQ	Recombinant Mouse Anti-IAV HA Antibody (VC167)	ELISA	Mouse antibody
MRO-2170CQ	Recombinant Mouse Anti-IAV HA Antibody (1E6A7)	WB, ELISA	Mouse antibody

CAT	Product Name	Application	Type
NABG-078	Recombinant Anti-IAV HA VHH Single Domain Antibody	FC, CA, IP, FuncS	Llama VHH
HPAB-0344CQ	Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0344CQ)	ELISA, Neut	Llama VHH
HPAB-0345CQ	Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0345CQ)	ELISA, Neut	Llama VHH

CAT	Product Name	Application	Type
TAB-H33	Anti-IAV HA Recombinant Antibody (Firivumab)	FC, IP, ELISA, Neut, FuncS, IF, ICC	IgG1 - kappa
TAB-027ML	Anti-IAV HA Recombinant Antibody (TAB-027ML)	ELISA, IHC, FC, IP, IF, FuncS	IgG1, κ
TAB-438CQ	Anti-IAV HA Recombinant Antibody (TAB-438CQ)	ELISA, IHC, FC, IP, IF, BL	IgG1, κ

CAT	Product Name	Application	Type
PFBL-483	Human Anti-IAV HA Recombinant Antibody; Fab Fragment (PFBL-483)	Neut	Human Fab
HPAB-0680-CN-F(E)	Human Anti-IAV HA Recombinant Antibody; Fab Fragment (HPAB-0680-CN-F(E))	ELISA, Neut	Human Fab
HPAB-0681-CN-F(E)	Human Anti-IAV HA Recombinant Antibody; Fab Fragment (HPAB-0681-CN-F(E))	ELISA, Neut	Human Fab
PFBC-426	Human Anti-IAV HA Recombinant Antibody; Fab Fragment (PFBC-426)	ELISA, Neut	Human Fab
PFBC-488	Recombinant Human Anti-IAV HA Antibody Fab Fragment (PFBC-488)	ELISA, Neut	Human Fab

CAT	Product Name	Application	Type
EPAF-0652CQ	Recombinant Mouse Anti-IAV HA Antibody (pSAN13.4.1)	ELISA	IgG

CAT	Product Name	Application	Type
HPAB-0870-CN-S(P)	Human Anti-IAV HA Recombinant Antibody; scFv Fragment (HPAB-0870-CN-S(P))	ELISA	Human scFv
FAMAB-0204WJ-S(P)	Mouse Anti-IAV HA Recombinant Antibody (clone H5.16); scFv Fragment	ELISA, WB, Neut	Mouse scFv
FAMAB-0205WJ-S(P)	Mouse Anti-IAV HA Recombinant Antibody (clone H5.22); scFv Fragment	ELISA, WB, Neut	Mouse scFv
FAMAB-0206WJ-S(P)	Mouse Anti-IAV HA Recombinant Antibody (clone H5.24); scFv Fragment	ELISA, WB, Neut	Mouse scFv
FAMAB-0207WJ-S(P)	Mouse Anti-IAV HA Recombinant Antibody (clone H5.31); scFv Fragment	ELISA, WB, Neut	Mouse scFv

CAT	Product Name	Application	Type
AFC-TAB-027ML	Afuco™ Anti-IAV HA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-027ML)	ELISA, IHC, FC, IP, IF, FuncS	ADCC enhanced antibody
AFC-TAB-438CQ	Afuco™ Anti-IAV HA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-438CQ)	ELISA, IHC, FC, IP, IF, BL	ADCC enhanced antibody
AFC-TAB-H33	Afuco™ Anti-IAV HA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H33)	FC, IP, ELISA, Neut, FuncS, IF	ADCC enhanced antibody

CAT	Product Name	Application	Type
MHC-YC213	H-2Kd/Influenza A virus Haemagglutinin (IYSTVASSL) MHC Pentamer	FCM

CAT	Product Name	Application	Type
FAMAB-0219WJ	Human Anti-IAV HA Recombinant Antibody (clone 16D11)	ELISA, WB, Neut	Human IgM

CAT	Product Name	Application	Type
VS-0424-XY118	AbPlus™ Anti-IAV HA Magnetic Beads (D1-1)	IP, Protein Purification

CAT	Product Name	Application	Type
VS-0325-FY191	Human Anti-IAV HA (clone 3E1) scFv-Fc Chimera	ELISA, Neut	Human IgG1, scFv-Fc

CAT	Product Name	Application	Type
VS-0625-XY50	Human Anti-IAV HA Vaccinal Antibody (VS-0625-XY50)	ELISA, Neut	Human IgG
VS-0625-XY51	Human Anti-IAV HA Vaccinal Antibody (VS-0625-XY51)	ELISA, BLI, Neut	Human IgG
VS-0625-XY52	Human Anti-IAV HA Vaccinal Antibody (VS-0625-XY52)	ELISA, BLI, Neut	Human IgG
VS-0625-XY53	Human Anti-IAV HA Vaccinal Antibody (VS-0625-XY53)	BLI, Neut	Human IgG

Specific Inquiry

Size:

Conjugation:

Endotoxin:

Purity:

Formats:

Isotype Switching:

Fc Engineering:

Modalities:

Add to compare

Request
Custom Production

custom production

See Our Custom Production in Action

Figure 1 Anti-HBV Recombinant Antibody (TAB-147) in SDS-PAGE

Download the full case study

Figure 1 Anti-HBV Recombinant Antibody (TAB-147) in SDS-PAGE

Download the full case study

Popular Products

Figure 2 Anti-Human TNF Antibody (TAB-010) in ELISA

Anti-Human TNF Recombinant Antibody (TAB-010) (CAT# TAB-010)
Application: WB, FC, IP, ELISA, Neut, FuncS, IF

Figure 2 Anti-Human IL12+IL23 Recombinant Antibody (TAB-063) in HPLC

Anti-Human IL12+IL23 Recombinant Antibody (Ustekinumab) (CAT# TAB-063)
Application: WB, FuncS, IF, Neut, ELISA, FC, IP

Figure 3 Anti-Human NCAM1 Therapeutic Antibody (TAB-188) in ELISA

Humanized Anti-NCAM1 Recombinant Antibody (clone Lorvotuzumab) (CAT# TAB-188)
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC

Figure 1 Anti-C. difficile Toxin A Recombinant Antibody (TAB-716) in SDS-PAGE

Anti-C. difficile Toxin A Recombinant Antibody (TAB-716) (CAT# TAB-716)
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC

Figure 2 IGF1R Recombinant Antibody (TAB-736) in HPLC

Anti-IGF1R Recombinant Antibody (TAB-736) (CAT# TAB-736)
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC

Figure 5 Anti-Human Mesothelin Recombinant Antibody (TAB-201) in HPLC

Anti-Human Mesothelin Recombinant Antibody (TAB-201) (CAT# TAB-201)
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC

Figure 2 Anti-Human PCSK9 Recombinant Antibody (TAB-H10) in HPLC

Anti-Human PCSK9 Recombinant Antibody (Bococizumab) (CAT# TAB-H10)
Application: WB, FC, IP, ELISA, Neut, FuncS, IF

Figure 2 Anti-Human NGF Recombinant Antibody (TAB-111) in ELISA

Anti-Human NGF Recombinant Antibody (TAB-111) (CAT# TAB-111)
Application: ELISA, FuncS, Inhib

Figure 2 Anti-Human CD24 Antibody (TAB-113CL) in WB

Anti-Human CD24 Recombinant Antibody (CAT# TAB-113CL)
Application:

Figure 2 Anti-Human MET Recombinant Antibody (TAB-521CL) in WB

Anti-Human MET Recombinant Antibody (TAB-521CL) (CAT# TAB-521CL)
Application: WB, FuncS

Figure 2 Anti-Human SLAMF7 Recombinant Antibody (TAB-570CL) in ELISA

Human Anti-SLAMF7 Recombinant Antibody (TAB-570CL) (CAT# TAB-570CL)
Application: IF, IHC, Inhib

Figure 3 Anti-Human EFNB2 Recombinant Antibody scFv Fragment (B11) (TAB-390MZ-S(P)) in Dot Blot

Anti-Human EFNB2 Recombinant Antibody scFv Fragment (B11) (CAT# TAB-390MZ-S(P))
Application: ELISA

Figure 4 Mouse Anti-MUC1 Recombinant Antibody (5E5) (TAB-418MZ) in HPLC

Mouse Anti-MUC1 Recombinant Antibody (TAB-418MZ) (CAT# TAB-418MZ)
Application: ELISA, FuncS, IHC, IF, FC, ADCC

Figure 1 Anti-Human NOTCH3 Recombinant Antibody (TAB-562MZ) in FC

Anti-Human NOTCH3 Recombinant Antibody (TAB-562MZ) (CAT# TAB-562MZ)
Application: ELISA, FuncS

Figure 2 Anti-Human F8 Antibody in HPLC

Recombinant Human Anti-F8 Antibody (BO2C11) (CAT# PABX-058)
Application: WB, ELISA, FuncS, Inhib, PK, IP, SPR

Figure 2 Human Anti-SLC30A8 Recombinant Antibody (clone C22) (HPAB-0040-CN) in SDS-PAGE

Human Anti-SLC30A8 Recombinant Antibody (clone C22) (CAT# HPAB-0040-CN)
Application: ELISA, WB, IHC

Figure 2 Human Anti-NOTCH4 Recombinant Antibody (HPAB-0068-CN) in HPLC

Human Anti-NOTCH4 Recombinant Antibody (HPAB-0068-CN) (CAT# HPAB-0068-CN)
Application: Neut, IF

Figure 4 Human Anti-TGFBR2 Recombinant Antibody (HPAB-0150-FY) in DB

Human Anti-TGFBR2 Recombinant Antibody (clone LY3022859) (CAT# HPAB-0150-FY)
Application: ELISA

Figure 2 Mouse Anti-PTPRC Recombinant Antibody (HPAB-0258-FY) in HPLC

Mouse Anti-PTPRC Recombinant Antibody (HPAB-0258-FY) (CAT# HPAB-0258-FY)
Application: ELISA

Figure 2 Recombinant Humanized Anti-Tau Antibody (MOB-0054SW) in ELISA

Human Anti-Tau Recombinant Antibody (MOB-0054SW) (CAT# MOB-0054SW)
Application: ELISA, FuncS

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare